Literature DB >> 7277631

The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.

P D Ellner, H C Neu.   

Abstract

A method for reporting minimum inhibitory concentration (MIC) data that facilitates interpretation by the clinician unfamiliar with clinically achievable drug levels is described. This system uses the inhibitory quotient, which is a number reflecting the multiple of the MIC that would be achieved. Inhibitory quotients are determined for blood, urine, bile, and CSF and reflect achievable drug levels in those body fluids. The use of inhibitory quotients can be extremely helpful to the physician in the rational selection of an appropriate antimicrobial agent.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7277631     DOI： 10.1001/jama.246.14.1575

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


  44 in total

1.  Effect of inoculum size on bacteriolytic activity of cefminox and four other beta-lactam antibiotics against Escherichia coli.

Authors:  F Soriano; R Edwards; D Greenwood
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 2.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

Review 3.  State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.

Authors:  J E Hoppe
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

4.  Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model.

Authors:  S Corvaisier; P H Maire; M Y Bouvier d'Yvoire; X Barbaut; N Bleyzac; R W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

5.  Correlation of in vitro activities of cephalothin and ceftazidime with their efficacies in the treatment of Staphylococcus aureus endocarditis in rabbits.

Authors:  R L Baker; R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

6.  Growth kinetics of L1210 leukemic cells exposed to different concentration courses of methotrexate in vitro.

Authors:  S Gimmel; H R Maurer
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis.

Authors:  J L Gaillard; P Cahen; C Delacourt; C Silly; M Le Bourgeois; C Coustère; J de Blic; G Lenoir; P Scheinmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

8.  Pharmacokinetics and clinical study of cefotetan in bile: prophylactic use in biliary tract surgery.

Authors:  P Cherrier; P Perrin; S Gueye; A M Bosio; P Tinel; P Blot; R Richer; F Fauvelle
Journal:  Pharm World Sci       Date:  1993-04-23

9.  Clinical and bacteriological experience with cefodizime in acute purulent exacerbations of chronic bronchitis.

Authors:  B I Davies; F P Maesen; J J van den Bergh; R J Costongs; W H Geraedts; H L Gubbelmans; J C Meek
Journal:  Infection       Date:  1992       Impact factor: 3.553

10.  Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

Authors:  Dean Hickman; Sudthida Vasavanonda; George Nequist; Lynn Colletti; Warren M Kati; Richard Bertz; Ann Hsu; Dale J Kempf
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.